Search for New Genetic Causes of Hypercalcemia by Massively Parallel

Status Completed

Clinical Trial Summary

Hypercalcemia, whether chronic or acute, exposes the patient to potentially serious complications (arrhythmias, nephrolithiasis, nephrocalcinosis, ...). Prevention relies primarily on effective etiological necessary for taking matched load. Under the French reference center for rare disorders of calcium and phosphorus, the investigators looked for mutations in the coding sequence of the CYP24A1 gene (encoding the enzyme responsible for the breakdown of vitamin D), among patients with hypercalcemia without hyperparathyroidism with hypersensitivity to vitamin D. However, only 25% of these patients have a genetic anomaly suggesting the involvement of other genes (Molin et al. 2015). Recently our team, combined with Kaufmann et al. (2014 JCEM) validated the interest of the determination of metabolites of vitamin D by liquid chromatography-tandem mass spectrometry (LC-MS / MS), as biological pre-screening stage for patients with hypercalcemia. The objective of this project is to complement the molecular and biochemical studies of patients without mutation of the coding sequence of CYP24A1, in a gene candidate approach using massively parallel sequencing (MPS) which allows to study a panel of gene potentially involved in disorder of metabolism of calcium and phosphorus. Highlighted variations will be tested in silico, and if possible in vitro. The investigators will also use LC-MS / MS to evaluate in vivo the effects of these variations on the metabolism of vitamin D, to develop a genotype / phenotype correlation. The work carried out within the Genetics Department Caen University Hospital in collaboration with physicians of the rare disease reference center of the metabolism of calcium and phosphorus should identify new genetic mechanisms underlying hypercalcemia. At the time of development of personalized medicine, it will adapt the therapy in patients at risk for metabolic complications and / or kidney following administration of vitamin D and finally to offer genetic counseling.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hypercalcemia

Clinical Trial Details

NCT number	NCT02908542
Study type	Observational
Source	University Hospital, Caen
Contact
Status	Completed
Phase
Start date	December 2015
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02711059` - Insulin Resistance in Primary Hyperparathyroidism	N/A
Recruiting	`NCT05585593` - Registry for Hypoparathyroidism Wuerzburg
Terminated	`NCT01725113` - Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol	Phase 4
Completed	`NCT01460030` - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase 3
Completed	`NCT00325104` - Cinacalcet to Treat Familial Primary Hyperparathyroidism	Phase 3
Recruiting	`NCT03935984` - Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity	Phase 4
Withdrawn	`NCT01329666` - Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D	Phase 2/Phase 3
Completed	`NCT00891813` - Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose	Phase 4
Completed	`NCT00674154` - Effect of Vitamin D Treatment in Primary Hyperparathyroidism	Phase 2/Phase 3
Completed	`NCT04299425` - Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy	N/A
Completed	`NCT00975221` - Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy	Phase 3
Withdrawn	`NCT03516747` - Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland	N/A
Completed	`NCT00485706` - Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients	N/A
Recruiting	`NCT01647503` - Differentially Expressed Proteins in Sporadic Parathyroid Tumors	N/A
Completed	`NCT01042626` - Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects	N/A
Not yet recruiting	`NCT01021280` - Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome	N/A
Not yet recruiting	`NCT01226810` - The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration	N/A
Terminated	`NCT00415584` - Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients	Phase 1/Phase 2
Completed	`NCT00581828` - Does Treatment of Hypovitaminosis D Increase Calcium Absorption?	Phase 4
Completed	`NCT00126386` - Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel — HyCaGene

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms